These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

171 related articles for article (PubMed ID: 37244440)

  • 1. Anti-IL-23 treatment with tildrakizumab can be effective in omalizumab-refractory chronic spontaneous urticaria: A case series.
    Bonnekoh H; Kiefer L; Buttgereit T; Kolkhir P; Lütke-Eversloh M; Scheffel J; Maurer M; Metz M
    J Allergy Clin Immunol Pract; 2023 Aug; 11(8):2578-2580.e1. PubMed ID: 37244440
    [No Abstract]   [Full Text] [Related]  

  • 2. Concurrent use of omalizumab and dupilumab in a 47-year-old woman with chronic spontaneous urticaria and atopic dermatitis.
    Holm JG; Sørensen JA; Thomsen SF
    Int J Dermatol; 2022 May; 61(5):e173-e174. PubMed ID: 34813086
    [No Abstract]   [Full Text] [Related]  

  • 3. Omalizumab is effective in patients with chronic spontaneous urticaria plus multiple chronic inducible urticaria.
    Skander D; Allenova A; Maurer M; Kolkhir P
    Eur Ann Allergy Clin Immunol; 2021 Mar; 53(2):91-93. PubMed ID: 32496030
    [No Abstract]   [Full Text] [Related]  

  • 4. A case of chronic spontaneous urticaria unresponsive to ligelizumab successfully treated with omalizumab.
    Russo F; Cortonesi G; Lazzeri L; Taddeucci P; Rubegni P
    Dermatol Ther; 2022 Nov; 35(11):e15859. PubMed ID: 36164841
    [No Abstract]   [Full Text] [Related]  

  • 5. Combined treatment with omalizumab and secukinumab in a patient with chronic spontaneous urticaria and psoriasis.
    Karstarli Bakay OS; Kacar N
    Dermatol Ther; 2022 Sep; 35(9):e15638. PubMed ID: 35703106
    [No Abstract]   [Full Text] [Related]  

  • 6. Real-life clinical practice with omalizumab in 134 patients with refractory chronic spontaneous urticaria: a single-center experience.
    Akdaş E; Adışen E; Öztaş MO; Aksakal AB; İlter N; Gülekon A
    An Bras Dermatol; 2023; 98(2):240-242. PubMed ID: 36567165
    [No Abstract]   [Full Text] [Related]  

  • 7. Recalcitrant chronic urticaria treated with dupilumab: Report of two instances refractory to H1-antihistamines, omalizumab and cyclosporine and brief literature review.
    Errichetti E; Stinco G
    Dermatol Ther; 2021 Mar; 34(2):e14821. PubMed ID: 33506984
    [No Abstract]   [Full Text] [Related]  

  • 8. Coesisting inflammatory skin diseases: Tildrakizumab to control psoriasis and omalizumab for urticaria.
    Diluvio L; Pensa C; Piccolo A; Lanna C; Bianchi L; Campione E
    Dermatol Ther; 2022 Apr; 35(4):e15359. PubMed ID: 35138022
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Does synthetic pharmacotherapy still have a place in treating chronic spontaneous urticaria?
    Thiede RM; Fazel M; MacDonald KM; Abraham I
    Expert Opin Pharmacother; 2022 Oct; 23(14):1563-1567. PubMed ID: 36173375
    [No Abstract]   [Full Text] [Related]  

  • 10. Selective IgE Deficiency Predicts Poor or No Response of Chronic Spontaneous Urticaria to Omalizumab.
    Picado C; Mascaró JJ; Vlagea A; Pascal M; Muñoz-Cano R; Bartra J
    J Investig Allergol Clin Immunol; 2022 Dec; 32(6):504-506. PubMed ID: 35225792
    [No Abstract]   [Full Text] [Related]  

  • 11. The Crucial Role of IgE as a Predictor of Treatment Response to Omalizumab in Chronic Spontaneous Urticaria.
    Maurer M; Kolkhir P; Moñino-Romero S; Metz M
    J Allergy Clin Immunol Pract; 2023 Aug; 11(8):2390-2391. PubMed ID: 37364668
    [No Abstract]   [Full Text] [Related]  

  • 12. Omalizumab serum levels predict treatment outcomes in patients with chronic spontaneous urticaria: A three-month prospective study.
    Ghazanfar MN; Bartko EA; Arildsen NS; Poulsen LK; Jensen BM; Enevold C; Holm JG; Woetmann A; Ødum N; Thomsen SF
    Clin Exp Allergy; 2022 May; 52(5):715-718. PubMed ID: 35278253
    [No Abstract]   [Full Text] [Related]  

  • 13. The use of omalizumab for treatment-refractory chronic spontaneous urticaria in a West Australian outpatient cohort.
    Farrah G; Stevenson B; Lie K; Brusch A
    Intern Med J; 2019 Apr; 49(4):526-528. PubMed ID: 30957371
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Novel Therapeutic Approaches and Targets for Treatment of Chronic Urticaria: New Insights and Promising Targets for a Challenging Disease.
    Martina E; Diotallevi F; Bianchelli T; Paolinelli M; Offidani A
    Curr Pharm Biotechnol; 2021; 22(1):32-45. PubMed ID: 32603278
    [TBL] [Abstract][Full Text] [Related]  

  • 15. "Omalizumab plus": Combining omalizumab with immunosuppression for treatment of refractory chronic urticaria: A multicenter UK series.
    Rutkowski K; Wagner A; Jui-Lin Choo K; Smith H; Savic S; Grattan CE
    J Allergy Clin Immunol Pract; 2021 Mar; 9(3):1400-1401.e2. PubMed ID: 33181342
    [No Abstract]   [Full Text] [Related]  

  • 16. H1-Antihistamines May No Longer Be Necessary for Patients With Refractory Chronic Spontaneous Urticaria After Initiation of Omalizumab.
    Ensina LF; Arruda LK; Campos RA; Criado RF; Rodrigues Valle S; Melo JM; Oliveira JC; Dortas JS; Cusato-Ensina AP; Camelo-Nunes IC; Agondi RC
    J Investig Allergol Clin Immunol; 2020 Apr; 30(2):145-147. PubMed ID: 31762438
    [No Abstract]   [Full Text] [Related]  

  • 17. Indication of Omalizumab for Chronic Urticaria Using the 'Urticaria Control Test' Instead of 'Urticaria Activity Score': Possible Impact for Health Systems.
    Sánchez J; Alvarez L; López JF
    Actas Dermosifiliogr; 2024 Jan; 115(1):T88-T90. PubMed ID: 37871896
    [No Abstract]   [Full Text] [Related]  

  • 18. Indication of Omalizumab for Chronic Urticaria Using the 'Urticaria Control Test' Instead of 'Urticaria Activity Score': Possible Impact for Health Systems.
    Sánchez J; Alvarez L; López JF
    Actas Dermosifiliogr; 2024 Jan; 115(1):88-90. PubMed ID: 36754254
    [No Abstract]   [Full Text] [Related]  

  • 19. Age and fast initial response predict omalizumab retreatment in chronic urticaria.
    Meertens MAJ; Luijf T; van Lindonk EAM; Soegiharto R; Assil S; Alizadeh Aghdam M; Kentie PA; Knulst AC; van Doorn MBA; Röckmann H
    J Allergy Clin Immunol Pract; 2023 Nov; 11(11):3556-3558.e1. PubMed ID: 37517795
    [No Abstract]   [Full Text] [Related]  

  • 20. Unique basophil microRNA signature in chronic spontaneous urticaria patients who respond to omalizumab.
    Al-Shaikhly T; MacDonald JW; Bammler TK; Altman MC; Ayars AG; Petroni DH; Tilles SA; Henderson WR
    Clin Exp Allergy; 2021 Dec; 51(12):1648-1652. PubMed ID: 34519110
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 9.